Ocrelizumab (Ocrevus) studies are typically MS protocols (relapsing or primary progressive). Infection and vaccine exclusions are common. We do not advise on infusion timing. Search the same name on ClinicalTrials.gov.
Also tagged in this snapshot for: Schizo-Affective Type of Psychosis · Schizophrenia · Multiple Sclerosis, Relapsing-Remitting · Multiple Sclerosis · Relapsing-remitting Multiple Sclerosis · Demyelinating Autoimmune Diseases, CNS · Autoimmune Diseases of the Nervous System · Nervous System Diseases · Demyelinating Diseases · Relapsing Remitting Multiple Sclerosis · Relapsing Multiple Sclerosis · Relapsing-Remitting Multiple Sclerosis (RRMS)
RecruitingPhase 1 / Phase 2Houston, Texas
Phase 1 / Phase 2: testing Ocrelizumab infusion for Schizo-Affective Type of PsychosisSome people who have what doctors currently call schizophrenia or bipolar disease may actually have a brain disease caused by auto-antibodies. Auto-antibodies are produced when the normal defense mechanism of the body goes wrong and begins to attack the body, similar to "friendly fire." Auto-antibodies attack brain receptors and then the person who has this problem begins to have hallucinations and other manifestations of schizophrenia, like feeling that people can see what they are thinking and also feeling that other people do not like them.
NCT03971487 · Official ClinicalTrials.gov record · The Methodist Hospital Research Institute
RecruitingNot a traditional drug phaseDetroit, Michigan
Not a traditional drug phase: Observation of Ocrelizumab as Treatment in RRMS Patients for Multiple Sclerosis, Relapsing-RemittingThe investigators intend to examine the effects of ocrelizumab use in African American multiple sclerosis disease course compared to Caucasian disease course utilizing imaging measures with magnetic resonance imaging (MRI) and optical coherence tomography angiography (OCT-A)..
NCT04458688 · Official ClinicalTrials.gov record · Wayne State University
RecruitingPhase 4Centennial, Colorado
Phase 4: testing Ocrelizumab at home for Multiple SclerosisThe goal is to assess the safety and effectiveness of home ocrelizumab infusion.
NCT04650321 · Official ClinicalTrials.gov record · University of Colorado, Denver
RecruitingPhase 3Lyon, Bron
Phase 3: testing Perfusion of treatment Rituximab for Multiple SclerosisThe goal of this randomly assigned clinical trial is to compare relapse remitting multiple sclerosis (RRMS) patients treated by ocrelizumab or by rituximab followed for 2 years. The main question it aims to answer is : • to demonstrate the non-inferiority of rituximab versus ocrelizumab in active relapsing MS patients on the % of patients without disease activity at 2 years.
NCT05758831 · Official ClinicalTrials.gov record · Rennes University Hospital
RecruitingPhase 3Amsterdam
Phase 3: testing Rituximab for Multiple SclerosisRationale: Ocrelizumab is widely and effectively used to treat relapsing multiple sclerosis (RMS). Phase II studies and data from large patient cohorts indicate that rituximab, another anti-CD20 monoclonal antibody, is probably equally effective and safe as ocrelizumab in the treatment of RMS.
NCT05834855 · Official ClinicalTrials.gov record · Amsterdam UMC, location VUmc
RecruitingPhase 3Poznan
Phase 3: testing CT-P53 for Relapsing-remitting Multiple SclerosisThis is a neither you nor the study doctors know who gets the real treatment, randomly assigned, active-controlled, parallel group, Phase 1/3 study to compare how well it works, PK, PD and overall safety of CT-P53 with Ocrevus in patients with Relapsing-remitting Multiple Sclerosis.
NCT05906992 · Official ClinicalTrials.gov record · Celltrion
RecruitingNot a traditional drug phaseBergen, Vestland
Not a traditional drug phase: Blood samples for PK for Relapsing Remitting Multiple SclerosisROS-MS is a clinical pharmacological substudy to the OVERLORD-MS study (NCT04578639), designed to examine the possibilities of personalized treatment with rituximab and ocrelizumab in patients with relapsing-remitting multiple sclerosis.
NCT06663111 · Official ClinicalTrials.gov record · Haukeland University Hospital
RecruitingPhase 3Pleven
Phase 3: testing Ocrelizumab for Multiple SclerosisThe study will measure the physical impact of MS from participant's perspective, provide continued access to ocrelizumab and assess the whether it is safe and how hard side effects are to live with of ocrelizumab. From Protocol Version 6 onwards, treatment within this study will be limited to the currently approved doses of ocrelizumab, 600 milligrams (mg), intravenous (IV) infusion or 920 mg, subcutaneous (SC) injection.
NCT06675955 · Official ClinicalTrials.gov record · Hoffmann-La Roche
RecruitingNot a traditional drug phaseAachen
Not a traditional drug phase: testing Ocrelizumab for Multiple SclerosisThe main purpose of the study is to evaluate participant satisfaction after administration of ocrelizumab subcutaneously (SC) after 12 months using the therapy administration satisfaction questionnaire subcutaneous (TASQ-SC).
NCT06780150 · Official ClinicalTrials.gov record · Hoffmann-La Roche
RecruitingPhase 3Scottsdale, Arizona
Phase 3: testing Remibrutinib oral treatment for Relapsing Multiple SclerosisThe purpose of this Phase 3b study is to assess the how well it works, whether it is safe and how hard side effects are to live with of remibrutinib after switching from ocrelizumab and compared to continuous ocrelizumab treatment, in patients living with relapsing multiple sclerosis (plwRMS).
NCT06846281 · Official ClinicalTrials.gov record · Novartis Pharmaceuticals
RecruitingPhase 3Montpellier
Phase 3: testing Platform therapies (Dimethyl Fumarate, Teriflunomide, Glatiramer Acetate, Beta-interferons) for Relapsing-Remitting Multiple Sclerosis (RRMS)Multiple sclerosis (MS), the main central nervous system autoimmune disorder, is the first cause of non-traumatic disability in young adults and has thus significant individual consequences with elevated public health cost. It commonly starts during the third and fourth decades.
NCT07189325 · Official ClinicalTrials.gov record · University Hospital, Montpellier
RecruitingNot a traditional drug phaseChicago, Illinois
Not a traditional drug phase: testing GLP-1 for Multiple SclerosisThe primary outcome measure is PIRA (progression independent of relapse activity), based primarily on clinical assessment, dichotomized as present or not. For Aim 1, the cohort, patient-derived disability status (PDDS) score, and ambulation score (self-reported) will be the primary endpoints of interest.
NCT07207148 · Official ClinicalTrials.gov record · Northwestern University
RecruitingPhase 2Camperdown, New South Wales
Phase 2: testing RO7268489 for Progressive Multiple SclerosisThe main purpose of this study is to assess the how well it works of RO7268489 in adults with progressive multiple sclerosis (PMS) receiving ocrelizumab. After the end of the neither you nor the study doctors know who gets the real treatment period, an open-label (OL) extension may allow eligible participants to receive open-label RO7268489.
NCT07282574 · Official ClinicalTrials.gov record · Hoffmann-La Roche
RecruitingPhase 3Nizhny Novgorod
Phase 3: testing BCD-281 for Relapsing-remitting Multiple Sclerosis (RRMS)The aim of this study is to compare the how well it works, safety profile, pharmacokinetics, pharmacodynamics, and immunogenicity of BCD-281 and the reference drug in subjects with relapsing multiple sclerosis.
NCT07321093 · Official ClinicalTrials.gov record · Biocad
RecruitingPhase 4Baltimore, Maryland
Phase 4: testing Ublituximab for Multiple SclerosisThe proposed study is a pilot study of ublituximab involving people with multiple sclerosis (MS) who are experiencing a "wearing off" phenomenon (return or worsening of MS-related symptoms) while being treated with ocrelizumab, and exploring whether switching to ublituzimab can resolve, improve or delay this phenomenon.
NCT07389590 · Official ClinicalTrials.gov record · Johns Hopkins University
RecruitingPhase 2San Francisco, California
Phase 2: testing HP 13C pyruvate injection for Multiple SclerosisThe main purpose of this study is to assess whether hyperpolarized carbon imaging in relapsing remitting multiple sclerosis (MS) patients can be used to predict response to anti-CD20 disease modifying therapy. Study procedures will include magnetic resonance imaging (MRI) assessments with a hyperpolarized pyruvate sequence, clinical assessment as well as blood markers of disease progression.
NCT07510607 · Official ClinicalTrials.gov record · Ari Green
RecruitingPhase 4Birmingham, Alabama
Phase 4: testing OCR SC for Multiple SclerosisThis study wants to assess the imaging biomarkers, patient outcomes, safety, tolerability, and treatment satisfaction of ocrelizumab (OCR) combined with recombinant human hyaluronidase (rHuPH20) administered subcutaneously (SC) in participants with relapsing multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS) after switching from another anti-cluster of differentiation 20 (aCD20) therapy approved for RMS (ofatumumab SC, ublituximab-xiiy intravenous \[IV\], ocrelizumab IV) or PPMS (ocrelizumab IV).
NCT07609719 · Official ClinicalTrials.gov record · Genentech, Inc.
RecruitingNot a traditional drug phaseLille
Not a traditional drug phase: testing ofatumumab for Multiple SclerosisThis real-life study aims to describe IgG levels after switching from ocrelizumab 600 mg IV every 6 to 8 months in Patients with Multiple Sclerosis (PwMS) to ofatumumab 20 mg SC every month and showing a decreasing level of IgG during treatment by ocrelizumab in real life practice in France over 24 months of follow-up. The primary objective is therefore to determine if the downward trend of IgG observed during ocrelizumab treatment is modified after a switch to ofatumumab, in PwMS treated during at least 18 months of ocrelizumab in real life practice, over 24 months of follow-up.
NCT07625800 · Official ClinicalTrials.gov record · University Hospital, Lille
RecruitingNot a traditional drug phaseChicago, Illinois
Not a traditional drug phase: testing Ocrevus Zunovo for Multiple SclerosisOcrevus Zunovo implementation, feasibility, acceptability, patient satisfaction, treatment persistence, and impact on MS disease outcomes will be analyzed in this mixed methods study. This study will incorporate clinical data and questionnaire results from MS patients who take Ocrevus Zunovo as well as qualitative interviews with MS patients, family members, and other individuals involved in Ocrevus Zunovo treatment.
NCT07710105 · Official ClinicalTrials.gov record · Northwestern University
RecruitingNot a traditional drug phaseSt Louis, Missouri
Not a traditional drug phase: testing Remibrutinib for Multiple Sclerosis (MS) - Relapsing-remittingREDEFINE-MS is a research study for people with relapsing multiple sclerosis (MS) who are participating in the RESHAPE-MS trial. The study aims to better understand how remibrutinib affects inflammation in the brain and spinal cord by using PET imaging, MRI scans, blood samples, and cerebrospinal fluid (CSF) samples collected before treatment and again six months later.
NCT07758270 · Official ClinicalTrials.gov record · Washington University School of Medicine
RecruitingNot a traditional drug phaseEast Hanover, New Jersey
A Study Comparing Effectiveness of Kesimpta® (Ofatumumab) Versus Ocrevus® (Ocrelizumab) in Real-world PracticeThis study aims to generate real-world evidence on the clinical effectiveness and economic burden of ofatumumab (OMB) versus ocrelizumab (OCR) in patients diagnosed with multiple sclerosis (MS) in the United States (US). Clinical effectiveness will be assessed using annualized relapse rate (ARR), while economic burden will be assessed using healthcare resource utilization (HCRU) and healthcare costs (HCC).
NCT07779460 · Official ClinicalTrials.gov record · Novartis Pharmaceuticals
RecruitingNot a traditional drug phasePardubice, Pardubice Region
Not a traditional drug phase: testing Ocrelizumab for Relapsing-Remitting Multiple SclerosisThe main purpose of the study is to assess patient-reported satisfaction with subcutaneous (s.c.) ocrelizumab administration in participants with relapsing-remitting multiple sclerosis (RRMS) who are treatment-who have not tried this kind of treatment before, switching from intravenous (i.v.) ocrelizumab to s.c. ocrelizumab, or switching from a prior disease-modifying therapy (DMT) to s.c.
NCT07827586 · Official ClinicalTrials.gov record · Hoffmann-La Roche
RecruitingNot a traditional drug phaseOklahoma City, Oklahoma
Early Versus Delayed Start of Ocrevus Zunovo for Relapsing Multiple SclerosisThis study will compare starting Ocrevus Zunovo soon after an active episode of relapsing multiple sclerosis (MS) with starting it later. Researchers want to learn whether starting treatment sooner reduces the number of MS relapses over 18 months.
NCT07878923 · Official ClinicalTrials.gov record · Oklahoma Medical Research Foundation
RecruitingNot a traditional drug phaseLondon
Not a traditional drug phase: testing High-efficacy disease-modifying therapy (HE-DMT) for Multiple SclerosisMultiple sclerosis (MS) is a condition in which the immune system damages the brain and spinal cord. Treatments called disease-modifying therapies can reduce inflammation and disease activity.
NCT07899502 · Official ClinicalTrials.gov record · Imperial College London